PURPOSE: Tumor-infiltrating lymphocytes (TILs) play a crucial role in host antitumor processes. High level of TILs is associated with better outcomes for patients. We aim to automatically quantify TILs without any nuclei annotation and further constr...
Programmed death-ligand 1 (PD-L1) is an important biomarker increasingly used as a predictive marker in breast cancer immunotherapy. Immunohistochemical quantification remains the standard method for assessment. However, it presents challenges relate...
Computational pathology models rarely utilise data that will not be available for inference. This means most models cannot learn from highly informative data such as additional immunohistochemical (IHC) stains and spatial transcriptomics. We present ...
European journal of cancer (Oxford, England : 1990)
40158294
BACKGROUND: Virtual staining is an artificial intelligence-based approach that transforms pathology images between stain types, such as hematoxylin and eosin (H&E) to immunohistochemistry (IHC), providing a tissue-preserving and efficient alternative...
Despite improvements in machine learning algorithms applied to digital pathology, only moderate accuracy, to predict molecular information from histology alone, has been achieved so far. One of the obstacles is the lack of large data sets to properly...
Colorectal cancer (CRC) ranks as the third most common and second deadliest cancer worldwide. The immune system, particularly tertiary lymphoid structures (TLS), significantly influences CRC progression and prognosis. TLS maturation, especially in th...
The journal of pathology. Clinical research
40050230
Breast cancer affects millions globally, necessitating precise biomarker testing for effective treatment. HER2 testing is crucial for guiding therapy, particularly with novel antibody-drug conjugates (ADCs) like trastuzumab deruxtecan, which shows pr...
PURPOSE: Pathologists diagnose prostate cancer (PCa) on hematoxylin and eosin (HE)-stained sections of prostate needle biopsies (PBx). Some laboratories use costly immunohistochemistry (IHC) for all cases to optimize workflow, often exceeding reimbur...
BACKGROUND: Treatment with HER2-targeted therapies is recommended for HER2-positive breast cancer patients with HER2 gene amplification or protein overexpression. Interestingly, recent clinical trials of novel HER2-targeted therapies demonstrated pro...
Immunohistochemistry (IHC) examination is essential to determine the tumour subtypes, provide key prognostic factors, and develop personalized treatment plans for breast cancer. However, compared to Hematoxylin and Eosin (H&E) staining, the preparati...